Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

Epithelial Ovarian Cancer — Treatment

First-line Second-line Later-line SECOND-LINE THIRD-LINE / LATER Epithelial ovarian cancer Frontline Maintenance by biomarker Recurrence · Pt-sensitive Recurrence · Pt-resistant Standard Cytoreduction + carbo/paclitaxel ± bev surgery + chemo BRCA+ Olaparib SOLO-1 ↗ HRD+ Olaparib + bevacizumab PAOLA-1 ↗ All-comers Niraparib PRIMA ↗ If used frontline Bevacizumab GOG-0218 ↗ Re-treat Platinum doublet ± bevacizumab OCEANS ↗ Maintenance PARP maintenance (if not used) SOLO-2 ↗ Cytotoxic Single-agent chemo ± bevacizumab AURELIA ↗ FRα+ Mirvetuximab soravtansine MIRASOL ↗